Condition: KRAS-mutant Non-small Cell Lung Cancer (NSCLC) · KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC) · KRAS-mutant Colorectal Cancer (CRC) · Sponsor: Kestrel Therapeutics, Inc.
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally to adults with advanced or metastatic solid tumors with certain KRAS mutations.
This description comes directly from the study's public registry record.
Kestrel Therapeutics, Inc. · 617-612-6810 · clinicaltrials@kestreltherapeutics.com
Always discuss trial participation with your own doctor first.
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Florida Cancer Specialists | Sarasota, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Mass General Brigham Cancer Institute at Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Sidney Kimmel Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
| Huntsman Cancer Institute, University of Utah | Salt Lake City, Utah, United States | Recruiting |
| NEXT Virginia | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07458347